Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Bethesda, Maryland 20892


Background: The NCI Surgery Branch has developed experimental therapies that involve taking white blood cells from patients' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells back to the patient. Objective: This study will collect white blood cells from normal volunteers and white blood cells and/or tumor cells, from patients who have been screened for and are eligible for a NCI Surgery Branch treatment protocol. The cells collected from normal volunteers will be used as growth factors for the cells during the period of laboratory growth. The cells and/or tumor from patients will be used to make the cell treatment product. Eligibility: Patients must be eligible for a NCI Surgery Branch Treatment Protocol Normal Volunteers must meet the criteria for blood donation Design Both patients and normal Volunteers will undergo apheresis. Patients will then undergo further testing as required by the treatment protocol. There is no required follow up for normal volunteers.

Study summary:

BACKGROUND: There are numerous clinical trials underway in the Surgery Branch, NCI in which patients are administered autologous lymphocytes with anti-tumor activity generated from either peripheral blood mononuclear cells (PBMC) or tumor infiltrating lymphocytes (TIL). All adoptive cell therapy protocols require that certain cell criteria be evaluated and met prior to enrollment. This protocol is also designed to serve as a biorepository for samples and associated data collected on patients enrolled on Surgery Branch protocols, which are now closed. Patients who were enrolled prior to 2003 were not enrolled on this protocol. Their tissue and data will now be retained on this protocol for long-term storage. The protocol is concerned with the retention of serum, CSF, bone marrow, ascites fluid, PBMCs, tumor, healthy tissue samples, and CD34 purified HSCS samples collected from patients with cancer to support basic science and clinical research activities of the Surgery Branch (SB) at the NIH Clinical Research Center and Center for Cancer Research. OBJECTIVES: - To obtain autologous blood, stem cells and/or tumor tissue from patients currently with cancer for laboratory analysis and ex vivo generation of autologous anti-tumor lymphocytes for future enrollment on a Surgery Branch adoptive cell therapy clinical trial. - To obtain allogeneic PBMC via apheresis, or blood samples from healthy volunteers for use in generating anti-tumor patient lymphocytes ex vivo. - To conduct genomic, proteomic and immunologic research studies on samples collected. ELIGIBILITY: Patients with cancer must be 16 years of age or older and meet the laboratory safety testing for infection included in all the cell therapy treatment trials. Healthy volunteers must meet the safety evaluation criteria established by the FDA for donation of blood products including HIV, HCV, HTLV, CMV, HBsAg, HBc, Trypanosoma cruzi, syphilis, and West Nile Virus. They must also meet the strict behavioral and medical history requirements. DESIGN: Once a cancer patient is determined to be a potential candidate for one of the Surgery Branch clinical trials, they will undergo an apheresis and/or tumor resection for future treatment and/or research purposes. In addition, this protocol will allow for the pheresis of healthy volunteers for allogeneic PBMC used in generating autologous antitumor lymphocytes in the laboratory, or for research purposes. No treatments, investigational or standard therapy, will be administered on this protocol.


- ELIGIBILITY CRITERIA FOR PATIENTS WITH A CURRENT DIAGNOSIS OF CANCER: INCLUSION CRITERIA: - Patients must have a form of cancer currently being studied with adoptive cell therapies in the Surgery Branch. - Ability of subject or Legally Authorized Representative to understand and sign the Informed Consent Document. - All participants greater than 18 years of age must be willing to sign a durable power of attorney. - Age greater than or equal to 16 years - Clinical performance status of ECOG 0 or 1. - Serology: - Seronegative for HIVantibody. (The experimental treatments being evaluated depend upon an intact immune system. Patients who are HIV seropositive can have decreased immune competence and thus may be less responsive to the experimental treatment and more susceptible to its toxicities). - Seronegative for hepatitis B surface antigen and seronegative for hepatitis C antibody. If hepatitis C antibody test is positive, then the patient must be tested for the presence of antigen by RT-PCR and be HCV RNA negative. - Lesions which will be harvested for the generation of TIL should be accessible via standard surgical or radiological techniques and be associated with acceptable morbidity EXCLUSION CRITERIA: - Active systemic infections, coagulation disorders, or other major medial illnesses of the cardiovascular, respiratory, or immune system. - Patients who cannot give proper informed consent to the adoptive cell experimental therapy due to an active psychiatric disorder or inability to understand the nature of the proposed therapy and attendant risk. ELIGIBILITY CRITERIA FOR NORMAL DONORS: INCLUSION CRITERIA: - Normal donors age greater than or equal to 18 years. - Seronegative for HBsAg, Anti-HBc, Anti-HCV, Anti-HIV-1/2, HIV- 1/HCV/HBV NAT, anti-HTLV-1/2, RPR, T. cruzi, and West Nile Virus NAT - Normal donors must meet the strict behavioral and medical history requirements EXCLUSION CRITERIA: - Has had babesiosis. - Is at risk or has Creutzfeld-Jakob Disease. - Is on steroid therapy or any other medication or has received vaccination that might interfere with cell preparation per Principal Investigator s discretion. - Has ongoing illness that would cause harm to the volunteer during the apheresis procedure as determined by the Principal Investigator. - Has had yellow jaundice, liver disease, or hepatitis since the age of 11. - Has uncontrolled diabetes. - Has a hematologic malignancy or any bleeding abnormalities. - Has received any type of organ transplant in the past 12 months. - Has undergone xenotransplantaion at any time. - Has received a dura mater graft. - If female, has been pregnant in the last six weeks. - Has had body piercing or tatoos within the past year. - Has spent time outside the United States to a restricted country. - Has participated in any high-risk activities.



Primary Contact:

Principal Investigator
Steven A Rosenberg, M.D.
National Cancer Institute (NCI)

Backup Contact:


Location Contact:

Bethesda, Maryland 20892
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: June 25, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.